Endogenex, developer of a procedure for treating type 2 diabetes, announced today that it appointed Stacey Pugh as its new CEO.
Pugh’s responsibilities at Minneapolis-based Endogenex include expanding the company’s clinical initiatives evaluating its ReCET procedure. ReCET — a novel, endoscopic, outpatient procedure — targets the underlying cellular abnormalities in the duodenum. These abnormalities contribute to the development and progression of type 2 diabetes.
According to Pugh’s LinkedIn page, the former Medtronic executive took over the corner office at Endogenex in December 2022.
“We are thrilled to have Stacey join the Endogenex team,” said Dr. James Eadie Endogenex board member and managing director, Santé. “Stacy is a proven leader with extensive experience in running global clinical and commercial stage medical device organizations. She is an expert in clinical affairs and market access strategy. Stacey has the track record of having led a high-growth business at scale while transforming clinical care, and now her skills will enable Endogenex to realize the significant potential of this technology.”
About new Endogenex CEO Stacey Pugh
Pugh’s experience includes time spent at Butterfly Network and Medtronic, among others.
She served as chief commercial officer at Butterfly Network and president of Medtronic’s Neurovascular business. Pugh spent the first half of her career in medical devices leading clinical and medical affairs teams. During that time, she worked for Medtronic, Covidien and Kinetic Concepts.
“I am excited to join the talented Endogenex team at this important stage,” said Pugh. “Endogenex is uniquely positioned to make a significant impact in the treatment of type 2 diabetes with a proprietary treatment targeted at the underlying causes of the disease.
“I look forward to partnering with our investigators and advisors as we further expand our clinical evidence and advance our technology to serve millions of people worldwide who suffer from this chronic condition.”
The ReCET Procedure:
Through applying highly controlled, non-thermal pulsed electric fields, ReCET aims to initiate the body’s natural regenerative process. This restores proper cellular signaling from the duodenum and improve metabolic function. In doing so, the procedure leads to better control of blood glucose levels, Endogenex says.
ReCET has received FDA breakthrough device designation.
Other companies develop diabetes reversal technology of different kinds. Fractyl Health develops the Revita outpatient procedure. The endoscopic procedure resurfaces the upper intestine lining (duodenal mucosa) in metabolic disease for patients with insulin-treated type 2 diabetes.
Virta Health develops a digital platform to enable personalized remote care in an effort to reverse diabetes. Its offerings include physician supervision, health coaches, an app and biomarker tracking tools. It also offers a personalized nutrition plan for its patients in the hopes of reversing type 2 diabetes.
Endogenex said its ReCET procedure is currently under evaluation in global pre-commercialization trials assessing safety and efficacy. They enrolled adults with type 2 diabetes who are inadequately controlled despite the use of insulin and non-insulin medications.